Illumina, Inc. (NASDAQ:ILMN) SVP Charles Dadswell sold 566 shares of the stock in a transaction on Monday, December 3rd. The shares were sold at an average price of $343.57, for a total value of $194,460.62. Following the sale, the senior vice president now owns 5,606 shares of the company’s stock, valued at approximately $1,926,053.42. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink.

ILMN opened at $334.21 on Thursday. The firm has a market capitalization of $49.13 billion, a PE ratio of 83.55, a price-to-earnings-growth ratio of 2.48 and a beta of 1.09. Illumina, Inc. has a 12-month low of $207.51 and a 12-month high of $372.61. The company has a quick ratio of 2.24, a current ratio of 2.46 and a debt-to-equity ratio of 0.24.

Illumina (NASDAQ:ILMN) last released its earnings results on Tuesday, October 23rd. The life sciences company reported $1.52 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.26 by $0.26. The company had revenue of $853.00 million during the quarter, compared to analyst estimates of $825.65 million. Illumina had a return on equity of 27.10% and a net margin of 21.09%. The company’s revenue for the quarter was up 19.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.11 earnings per share. Sell-side analysts anticipate that Illumina, Inc. will post 5.75 EPS for the current fiscal year.

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Standard Life Aberdeen plc raised its holdings in shares of Illumina by 31.1% during the second quarter. Standard Life Aberdeen plc now owns 34,546 shares of the life sciences company’s stock worth $9,650,000 after acquiring an additional 8,199 shares in the last quarter. Jackson Square Partners LLC raised its holdings in shares of Illumina by 7.7% during the third quarter. Jackson Square Partners LLC now owns 1,429,221 shares of the life sciences company’s stock worth $524,609,000 after acquiring an additional 102,639 shares in the last quarter. Waters Parkerson & CO. LLC purchased a new stake in shares of Illumina during the second quarter worth $223,000. Handelsbanken Fonder AB purchased a new stake in shares of Illumina during the third quarter worth $8,442,000. Finally, Bank of Nova Scotia raised its holdings in shares of Illumina by 216.4% during the second quarter. Bank of Nova Scotia now owns 59,185 shares of the life sciences company’s stock worth $16,529,000 after acquiring an additional 40,478 shares in the last quarter. Institutional investors own 88.91% of the company’s stock.

A number of equities research analysts have recently commented on the company. Zacks Investment Research downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Wednesday, October 24th. Barclays increased their price objective on Illumina from $350.00 to $370.00 and gave the company an “overweight” rating in a research report on Wednesday, October 24th. BidaskClub downgraded Illumina from a “buy” rating to a “hold” rating in a research report on Tuesday, October 16th. Deutsche Bank increased their price objective on Illumina to $350.00 and gave the company a “buy” rating in a research report on Friday, October 12th. Finally, ValuEngine downgraded Illumina from a “strong-buy” rating to a “buy” rating in a research report on Thursday, October 11th. Six investment analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $330.94.

ILLEGAL ACTIVITY WARNING: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.watchlistnews.com/illumina-inc-ilmn-svp-charles-dadswell-sells-566-shares/2664977.html.

About Illumina

Illumina, Inc provides sequencing and array-based solutions for genetic analysis. The company operates in two segments, Core Illumina and Consolidated VIEs. It offers sequencing by synthesis technology that provides researchers with various applications and the ability to sequence mammalian genomes; and arrays for a range of deoxyribonucleic acid and RNA analysis applications, including single nucleotide polymorphism genotyping, copy number variations analysis, gene expression analysis, and methylation analysis, as well as allow the detection of known genetic markers on a single array.

Further Reading: How can you know how many shares are floating?

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.